Project Duration: 2012-2025
MOHCCN Consortium: BC Cancer Consortium.
Investigators: Drs. M. Marra, J. Laskin, S. Jones, D. Renouf, D. Regier, K. Schrader, S. Sun, H. Lim, S. Yip, R. Holt, S. Aparicio, N. Caron.
Partners: BC Cancer, Canada’s Michael Smith Genome Sciences Centre.
POG is a world-leading research program that is using rapid, clinically deployed whole genome and transcriptome analysis of incurable cancers to identify and better understand genomic driver alterations and therapeutic vulnerabilities. The motivating hypothesis is that routine analysis of genomic, transcriptomic, clinical, and treatment data from incurable cancers will inform treatment planning across cancer types. The analysis of a breadth of malignancies is driven by the participation of approximately 80 percent of all medical oncologists in BC, with the support and participation of teams e.g. pathologists, radiologists, scientists, residents, research trainees, managers and study coordinators. To date, POG has analyzed cancers from more than 25 broad cancer types, which encompass 190 oncotree terms. POG has led to involvement in clinical trials and the publication of novel mutations and treatment strategies.